Shares in London-based Amryt Pharma (AIM: AMYT) were up around 50% in morning trading on Tuesday, following positive top-line results from a Phase III study of Filsuvez (oleogel-S10), a topical therapeutic gel.
The firm, which is focused on serious and life-threatening diseases, said the EASE trial met its primary endpoint in the treatment of a rare skin condition.
Amryt has been trialing the therapy as an option for dystrophic and junctional Epidermolysis bullosa (EB), a serious, chronic and rare condition for which there are no approved treatments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze